Section Review Oncologic, Endocrine & Metabolic: Gene therapy for cancer therapeutics

This publication has 58 references indexed in Scilit:

• Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo.
  Proceedings of the National Academy of Sciences, 1996
• In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence
  Nature, 1994
• Reduction of erbB2 Gene-Product in Mamma Carcinoma Cell Lines by erbB2 mRNA-Specific and Tyrosine Kinase Consensus Phosphorothioate Antisense Oligonucleotides
  Biochemical and Biophysical Research Communications, 1994
• Inhibition of Nuclear Protein Binding to the Human Ki-ras Promoter by Triplex-Forming Oligonucleotides
  Biochemistry, 1994
• Triplex formation inhibits HER-2/neu transcription in vitro.
  Journal of Clinical Investigation, 1993
• Expression of transforming growth factor ? antisense mRNA inhibits the estrogen-induced production of TGF? and estrogen-induced proliferation of estrogen-responsive human breast cancer cells
  Journal of Cellular Physiology, 1993
• Binding of triple helix forming oligonucleotides to sites in gene promoters
  Biochemistry, 1991
• A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization.
  Molecular and Cellular Biology, 1991
• Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide
  The Lancet, 1990
• Site-Specific Oligonucleotide Binding Represses Transcription of the Human c- myc Gene in Vitro
  Science, 1988